Biohaven Shares Tick Higher After Phase 2 Obesity Trial Reaches Full Enrollment
Biohaven Ltd. shares rose after the company confirmed that its Phase 2 clinical trial of taldefgrobep alfa for obesity has reached full enrollment. The randomized, double-blind, placebo-controlled study is testing once-weekly and once-monthly dosing in adults with overweight and obesity, and includes a 24-week double-blind period followed by a 24-w…